This technology includes Streptococcus pneumoniae isolates collected through CDC’s Global Strain Bank project with particular serotypes. They were collected as part of routine clinical and surveillance activities and have a wide variety of uses including research, diagnostic, and the development of therapeutics.
This technology includes mycoplasma-free PV (isolated in 1882) and SAD/ERA (isolated in 1935) virus stock for rabies vaccine development. Rabies virus causes a nearly uniformly fatal disease, but can be prevented by timely vaccination. Two of the most common rabies virus vaccine strains are PV and SAD/ERA, both of which have had extensive passaging in both animals and subsequently cultivation in cells. The rabies vaccine virus stocks stored at CDC are heavily contaminated by mycoplasma.
This technology includes a new reverse genetics-based approach that generates Crimean-Congo hemorrhagic fever virus (CCHF) viral replicon particles (CCHF VRPs) to be developed into a vaccine for CCHFV. With mortality rates as high as 80% and with no FDA-approved vaccines or therapeutics, CCHFV is considered a dangerous emerging human pathogen. Unlike transcriptionally competent virus like particles (tc-VLPs), that only include CCHFV virus proteins and minigenome RNA, VRPs undergo one full round of replication closely mimicking authentic viral replication.
This technology includes a vaccine for immunizing against different strains of rotavirus. Rotavirus is a highly contagious virus causing severe diarrhea in children and can be fatal. Due to various circumstances, the number of available, efficacious vaccines for rotavirus is declining at a time when infections remain a serious worldwide problem. This technology meets the need for vaccines against human rotavirus A strains of both common and less common types.
This technology includes a combined IPV and IRV for co-administration and global immunization against polio and rotavirus among children. Currently IPV and IRV are administered by parenteral administration in two separate injections, which complicates routine immunization schedules and is costly.
This technology includes natural Yellow Fever Virus, Zika Virus, and Powassan Virus isolates for various uses in research and development of diagnostics and immunizations.
This technology includes isolates of the Dengue Virus (type 2) which can be used to develop diagnostic tests, antivirals and vaccinations. These isolates are from Puerto Rico DENV-2 and have complete whole genome sequencing completed. Additionally, these isolates represent current stains of Dengue Virus which are circulating in the Caribbean.
This technology includes clean, mycoplasma-free, rabies virus stocks for use in vaccine manufacturing. Rabies virus causes a nearly uniformly fatal disease, but can be prevented by timely vaccination. An inactivated rabies vaccine for human use was first prepared in cell culture in 1964, using the Pitman-Moore (PM) strain of fixed rabies virus. Typical rabies vaccine virus stocks stored at the Centers for Disease Control are heavily contaminated by mycoplasma, there this stock provides an alternative supply which is free of mycoplasma.
This technology includes a new concept to develop a bivalent IRV-IPV combination vaccine against rotavirus and polio using a dissolving microneedle patch. Specifically, we describe the formulation for IRV, the fabrication of a microneedle patch for combined IRV-IPV, and the proof of concept for assessing potential interference of immunogenicity and dose sparing in animal studies. Licensed oral rotavirus vaccines, while effective in developed and middle-income countries, are significantly less effective in reducing cases of severe diarrhea among children in developing countries.
This technology includes a novel, isolated reassortant mammalian Orthoreovirus (MRV) isolated from pigs with neurological symptoms, for use in the development of vaccines and diagnostic tests. This isolate has S1 gene from MRV1 closed to bovine isolated, M2 gene from MRV2 and other 8 genes from MRV3 based on full-genome sequence analysis. MRV3 has been reported and isolated from the US pigs with diarrhea symptom. Compared to the reported swine MRV3 isolates that cause diarrhea in pigs, the novel reassortant MRV causes neurological disease in pigs.